Anti-Radiation Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

Anti-Radiation Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

Anti-Radiation Drugs Market By Compound (Potassium Iodide, Prussian Blue, Diethylenetriamine Pentaacetic Acid, Colony Stimulating Factors, And Others), Indication (Acute Radiation Syndrome, Cancer Treatment, And Others), Radiation Type (Ionizing Radiations And Non-Ionizing Radiations), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, And Others) and geography is expected to grow at a steady CAGR forecast till 2030 owing increasing number side effects associated cancer diagnostic procedures and surge in risk of exposure to radiological or nuclear accidents around the globe during the forecast period.

The global Anti-Radiation Drugs market is estimated to grow at a CAGR of 8.79% during the forecast period from 2024 to 2030. The demand for anti-radiation drugs is primarily being boosted owing to the increasing number of side effects associated with cancer diagnostic procedures, the surge in the risk of exposure to radiological or nuclear accidents, and the rising inclination of nuclear superpower countries towards radioactive protection among others, thereby contributing to the overall growth of the anti-radiation drugs market during the forecast period from 2024-2030.

Anti-Radiation Drugs Market Dynamics:

According to the FDA, most medical imaging equipment such as Computed Tomography (CT), radiography, and conventional mammography all use ionizing radiation to generate images of the body. These ionizing radiations have enough potential to damage DNA and elevate the risk of developing cancer.

In addition, the National Toxicology Program (NTP) formed from parts of several different US government agencies, including the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), has classified x- and gamma radiation as a human carcinogen.

As per the NCI (National Cancer Institute) 2019, patients who have had multiple CT scans before the age of 15 were found to have an increased risk of developing leukemia, and brain tumors. Moreover, sometimes the high levels of radiation exposure can affect tissues and cause hair loss, skin reddening, cataracts, and other problems that might aggravate the need for anti-radiation treatments in the form of drugs.

Therefore, safety concerns due to exposure to high ionizing radiations and their side effects during diagnostic imaging are expected to bolster the demand for anti-radiation pharmaceuticals.

Hence, the interplay of all the above-mentioned factors is anticipated to increase the overall market growth for anti-radiation drugs during the forecast period from 2024 - 2030.

However, the lack of disease-related expertise among healthcare professionals, and ethical and legal complications for finding adequate sample size for clinical trials and research, among others may restrict the growth of the overall market for anti-radiation drugs during the forecast period.

Anti-Radiation Drugs Market Segment Analysis:

Anti-Radiation Drugs Market by Compound (Potassium Iodide, Prussian Blue, Diethylenetriamine Pentaacetic Acid, Colony Stimulating Factors, and others), Indication (Acute Radiation Syndrome, Cancer Treatment, and others), Radiation Type (Ionizing Radiations and Non-Ionizing Radiations), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and others) and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the Compound type segment of the anti-radiation drugs market, the Potassium iodide sub-category is expected to amass a significant revenue share in the year 2023. This can be ascribed to the various characteristics and advantages associated with potassium iodide.

One form of radioactive material that can be used to help prevent radioactive iodine (I-131) from being absorbed by the thyroid is potassium iodide (KI), a non-radioactive form of iodine. During a nuclear accident, radioactive iodine may be released into the environment in a plume or cloud and subsequently contaminate soil, surfaces, food, and water.

The best results from KI come from taking it immediately before or right after internal radioactive iodine contamination. The amount of radioactive iodine that enters the body and how quickly it is absorbed by the body both affect how effective KI is.

KI is usually presented in scored tablets, which facilitates fractionation for pediatric dosage. The tablets have also been proven as a protective agent during wars for mass protection.

According to the European Commission (2022) in 2022, during the Ukraine war, the Government of Ukraine ordered KI pills from the European Government as a preventative safety measure to increase the level of protection around the Zaporizhzhia nuclear power plant. The potassium iodide tablets would be used in limited scenarios to avoid that inhaled or swallowed radioactive iodine is absorbed by the thyroid; to which the EU Emergency Response Coordination Centre swiftly mobilized 5.5 million potassium iodide tablets via the EU Civil Protection Mechanism for Ukraine.

Therefore, considering the advantages associated with KI in radioactive protection, it is expected to thereby contribute to the overall market growth for anti-radiation drugs during the forecast period from 2024 to 2030.

North America Is Expected To Dominate The Overall Anti-Radiation Drugs Market:

Among all the regions, North America is estimated to account for the largest share of the Anti-Radiation Drugs market in the year 2023. Owing to the significance of key growth factors such as the presence of a large patient population associated with various diseases including cancers, rising diagnostic procedures, and government protection activities for the masses in North America, the market is expected to witness substantial growth during the forecast period from 2024-2030.

For instance, one of the prominent reasons for the requirement for a high number of anti-radiation drugs is the surge in the prevalence of cancers in the United States. As per the figures mentioned by the American Cancer Society, 2024 data in 2024, it was estimated that approximately 2 million new cancers will be diagnosed in the United States. This ultimately would lead to more demand for anti-radiation drugs resulting from a large number of cancer diagnostic procedures. Moreover, the extensive focus on clinical research and the presence of key players in the region from the pharmaceutical domain further help in the growth of the US anti-radiation drugs treatment market.

Furthermore, in 2022, The US Department of Health and Human Services (HHS) spent USD 290 million on a drug to treat radiation sickness in the event of a nuclear emergency; buying the drug Nplate from Amgen USA Inc. as part of long-standing, ongoing efforts to be better prepared to save lives following radiological and nuclear emergencies.

Therefore, the interplay of all the above-mentioned factors is expected to aid in the growing demand for anti-radiation drugs, thus driving the overall regional market for North America Anti-Radiation Drugs.

Anti-Radiation Drugs Market Key Players:

Some of the key market players operating in the anti-radiation drugs market include Novartis AG, Anbex Inc., Amgen Inc., Myelo Therapeutics, Arco Pharmaceuticals LLC, BTG International Inc., Cellphire Inc., Darnitsa, Enzychem Lifesciences Corporation, Humanetics Corporation, Mission Pharmacal Company, Chrysalis BioTherapeutics Inc., Pluri Inc., Partner Therapeutics, HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG., RxBio Inc., Coherus Biosciences, Onconova Therapeutics, Jubilant Life Sciences, Soligenix Inc., and others.

Recent Developmental Activities In The Anti-Radiation Drugs Market:

In September 2023, the U.S. Department of Defense awarded Edina-based Humanetics a USD 20 million contract to develop a pill that prevents radiation damage in military members and first responders affected by events such as nuclear accidents, warfare, and dirty bombs.

In May 2023, the first-in-human clinical trial of an experimental oral drug for removing radioactive contaminants from inside the body, testing the safety, tolerability, and processing in the body of escalating doses of the investigational drug product HOPO 14-1 was initiated in healthy adults. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, was funding the Phase 1 trial, which was sponsored and conducted by SRI International of Menlo Park, California.

In March 2022, Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body. These patients have already been treated with other anticancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy).

Key Takeaways From The Anti-Radiation Drugs Market Report Study

Market size analysis for current Anti-Radiation Drugs market size (2023), and market forecast for 6 years (2024-2030)

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global Anti-Radiation Drugs market.

Various opportunities available for the other competitors in the Anti-Radiation Drugs market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current Anti-Radiation Drugs market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for Anti-Radiation Drugs market growth in the coming future?

Target Audience Who Can Benefit From This Anti-Radiation Drugs Market Report Study

Anti-Radiation Drugs product providers

Research organizations and consulting companies

Anti-Radiation Drugs-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in Anti-Radiation Drugs

Various end-users who want to know more about mental disorders and its related treatment equipment market, along with the latest technological developments in the Anti-Radiation Drugs market.

Frequently Asked Questions For The Anti-Radiation Drugs Market:

1. What is meant by Anti-Radiation Drugs?

Anti-radiation drugs are specially formulated medications that could potentially help limit or treat the health effects of certain types of radiation in a radiological or nuclear emergency.

2. What is the market for global Anti-Radiation Drugs?

The Anti-Radiation Drugs market is estimated to grow at a CAGR of 8.79% during the forecast period from 2024 to 2030.

3. What are the drivers for the global Anti-Radiation Drugs market?

The demand for Anti-Radiation Drugs is primarily being boosted owing to the increasing number of side effects associated with cancer diagnostic procedures, the surge in the risk of exposure to radiological or nuclear accidents, and the rising inclination of nuclear superpower countries towards radioactive protection among others, thereby contributing to the overall growth of the anti-radiation drugs market during the forecast period from 2024-2030.

4. Who are the key players operating in the global Anti-Radiation Drugs market?

Some of the key market players operating in the Anti-Radiation Drugs market include Novartis AG, Anbex Inc., Amgen Inc., Myelo Therapeutics, Arco Pharmaceuticals LLC, BTG International Inc., Cellphire Inc., Darnitsa, Enzychem Lifesciences Corporation, Humanetics Corporation, Mission Pharmacal Company, Chrysalis BioTherapeutics Inc., Pluri Inc., Partner Therapeutics, HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG., RxBio Inc., Coherus Biosciences, Onconova Therapeutics, Jubilant Life Sciences, Soligenix Inc., and others.

5. Which region has the highest share in the Anti-Radiation Drugs market?

North America is expected to dominate the overall Anti-Radiation Drugs market during the forecast period from 2024-2030. Owing to the significance of key growth factors such as the presence of a large patient population associated with various diseases including cancers, diagnostic procedures, and government protection activities for the masses in North America, the market is expected to witness substantial growth during the forecast period from 2024-2030.